Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain

NCT ID: NCT00291148

Last Updated: 2012-07-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 75 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-03-31
• Study Completion Date: 2012-07-31

Brief Summary

This is a comparative drug trial involving patients with clinically definite Multiple Sclerosis and documented neuropathic pain. Patients will be randomized to receive treatment with either paroxetine or pregabalin. After dose titration, participants will complete various pain scale assessments at several points during the study in order to determine the effectiveness of their assigned pain medication.

Detailed Description

General Objective:

To determine the effectiveness of drug treatment in the management of MS-induced neuropathic pain.

Specific Objectives:

• Comparatively assess the effectiveness and safety profile of pregabalin (Lyrica) and paroxetine (Paxil) in managing MS-induced neuropathic pain.
• Comparatively assess the effectiveness of pregabalin (Lyrica) and paroxetine (Paxil) in improving the quality-of-life associated with MS-induced neuropathic pain.

Study Design:

A comparative single center, randomized, open-label study involving patients with multiple sclerosis (MS) - induced neuropathic pain receiving treatment with either pregabalin (Lyrica®) or paroxetine (Paxil®).

The study will run for approximately one year, requiring individual participants' involvement for 8 weeks.

Participant Selection:

Individuals with clinically definite MS presenting with symptoms of neuropathic pain (as determined by clinician) that express interest in the study will be screened for eligibility.

Inclusion Criteria:

• Patients presenting with symptoms of neuropathic pain as determined by clinician, with a minimum VAS pain score of 40mm as determined by a baseline score (0mm = no pain, 100mm = worst pain).
• Male and female patients between the ages of 18 and 65 years old.
• Clinically definite multiple sclerosis as defined by clinical history review, neurological examination and positive MRI.
• EDSS scores of < 6.0.
• No known hypersensitivity to the study medications.
• Negative serum pregnancy test for all female patients of childbearing age; not currently breastfeeding.
• Not currently treated with pregabalin, gabapentin, paroxetine or another SSRI.
• No previous treatment failures with pregabalin or paroxetine.
• Baseline creatinine clearance (Clcr) of > 50mL/min.
• No significant hepatic insufficiency.
• If on other pain medications, must be on stable dose for at least 6 months and other medications must not elicit significant drug-drug interactions with study medications.

Study Procedures:

After obtaining informed consent (Visit 1), participants undergo various assessments, including pain/quality-of-life analyses (SF-MPQ, SF-36, VAS), physical/neurological exam and a standard blood test. Based on above inclusion criteria, participants will be randomized to either Group A (paroxetine) or Group B (pregabalin). Participants will be provided with prescriptions for assigned study medications as well as dosing instructions. A pain diary consisting of a single VAS scale will be provided to the participants, which are to be completed daily upon waking and should be used to rate the individual's average pain over the last 24 hours. Dosages of study medications will be titrated slowly over 3 weeks to lower likelihood of adverse events. After the three week titration phase, participants will return to the clinic (Visit 2) for a follow-up. Pain/quality-of-life assessments (as at Visit 1) will be completed again at this visit. In addition, average pain scores will be determined from daily pain diaries. Adverse events will be discussed and individual tolerability will be assessed. At this point, it will be determined if the patient will be maintained at the target dosage or if the dosage will be lowered to accommodate patient tolerability. Participants will be maintained at determined maintenance dose for 5 weeks, after which they will return to the clinic (Visit 3) for a final follow-up assessment. Participants will complete final pain/quality-of-life assessments, as well as the "Patient-rated Global Impression of Change". Adverse events and average pain scores will be reviewed. At the conclusion of the 8-week treatment phase, participants will have the option of remaining on their current study medication or be tapered off.

Conditions

Neuropathic Pain; Multiple Sclerosis

Keywords

Neuropathic pain; Multiple Sclerosis; pregabalin; paroxetine

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Paroxetine

Group Type: ACTIVE_COMPARATOR

paroxetine

Intervention Type: DRUG

pregabalin

Group Type: ACTIVE_COMPARATOR

pregabalin

Intervention Type: DRUG

Interventions

paroxetine

Intervention Type: DRUG

pregabalin

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• • Patients presenting with symptoms of neuropathic pain as determined by clinician, with a minimum VAS pain score of 40mm as determined by a baseline score (0mm = no pain, 100mm = worst pain).

• Male and female patients between the ages of 18 and 65 years old.
• Clinically definite multiple sclerosis as defined by clinical history review, neurological examination and positive MRI.
• EDSS scores of < 6.0.
• No known hypersensitivity to the study medications.
• Negative serum pregnancy test for all female patients of childbearing age; not currently breastfeeding.
• Not currently treated with pregabalin, gabapentin, paroxetine or another SSRI.
• No previous treatment failures with pregabalin or paroxetine.
• Baseline creatinine clearance (Clcr) of > 50mL/min.
• No significant hepatic insufficiency.
• If on other pain medications, must be on stable dose for at least 6 months and other medications must not elicit significant drug-drug interactions with study medications.

Exclusion Criteria

-

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Manitoba

OTHER

Sponsor Role: lead

Principal Investigators

Micheal P Namaka, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Manitoba

Dana A Turcotte, BSc Pharm

Role: PRINCIPAL_INVESTIGATOR

University of Manitoba

Locations

Multiple Sclerosis Clinic, Health Sciences Centre

Winnipeg, Manitoba, Canada

Countries

Canada

Other Identifiers

MS_B2005:168

Identifier Type: -

Identifier Source: org_study_id